| 영문 | cell-mediated immunity | 한글 | 세포매개면역 |
|---|---|---|---|
| 설명 | 면역이란 신체를 외부의 물질로부터 보호하는 행위를 말한다. 여기에는 특이적 면역과 비특이적 면역의 두 가지가 있다. 비특이적 면역이라함은 특정한 물질에 관계하는 면역이 아니라 특정 대상이 없이 모든 외부 물체에 작용할 수 있는 면역을 말한다. 여기에는 소변의 흐름, 눈물의 흐름, 피부의 비투과성 등의 기계적인 것도 포함되고 피속에 돌아다니는 세포 중에서 비특이적으로 외부의 물질을 포식하는 세포들(예를 들면 큰포식세포(macrophage)의 활동도 포함이 된다. 세포매개면역이란 특이한 물질을 감지할 수 있는 세포를 생성하게 하여 그것으로 하여금 그 물질을 포식하게 하는 것을 말한다. |
||
| 영문 | nerve cell | 한글 | 신경세포 |
|---|---|---|---|
| 설명 | 신경세포는 올바른 신경전달을 위한 각 부분별로 나뉘어져 있다. 신경세포에서는 전해져오는 자극을 전기적인 신호로 바뀌어 보내거나 받게 된다. 이런 전기적인 현상은 각 신경세포내에 존재하는 각 이온채널(ion channel: ion이란 나트륨, 칼륨 등을 지칭하는 말들로써, 이들이 세포막에 의해 나뉘어질 때 생기는 전압차가 전기적 자극을 일으키고 유지하는데 결정적인 역할을 한다)들의 작용에 의해 이루어지게 된다. |
||
| 영문 | glia cell | 한글 | 아교세포 |
|---|---|---|---|
| 설명 | 신경세포 사이에서 그물구조를 이루며 이를 지지하는 조직. 신경아교세포는 신경모세포와 갈라진 아교모세포가 다시 여러 형태로 분화-성장한 것이다. 뇌실이나 척수중심관의 벽을 덮고 원주상 또는 입방형이며, 초기에는 유리면에 섬모가 있다. 대형세포는 별뇌실막세포는 아교세포라고 하며, 신경세포나 신경섬유 사이에 산재한다. 그 외에 희소돌기아교세포도 포함된다. |
||
| 영문 | reserve cell | 한글 | 예비세포 |
|---|---|---|---|
| 설명 | 일반적으로 상피조직에서 이미 있던 상피세포가 손상을 받아 사멸하면 매꿔지는 그 밑에 있는 미분화세포 예를 들면, 기관지 내표면을 덮는 중층 원주 상피의 기저에 있는 작은 미분화 상피 세포. |
||
| 영문 | stem cell | 한글 | 줄기세포, 간세포 |
|---|---|---|---|
| 설명 | 자기 복제를 하여 자신을 존속시키면서 한편으로는 증식과 분화를 하여 새로운 세포를 형성하는 세포로서 조혈줄기세포가 대표적이다. 조혈줄기세포는 골수에 있는 세포로서 모든 혈구세포가 여기에서 분화되어 발생한다. |
||
| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
|---|---|
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| PPT | parietal pleural tissue; partial prothrombin time; peak-to-peak threshold; Pfeiffer-Palm-Teller [syn... |
| HEC | hamster embryo cell; Health Education Council; human endothelial cell; hydroxyergocalciferol; hydrox... |
| endothelial myeloma | A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy. (27 Sep 1997) |
|---|---|
| endothelial relaxing factor | A molecule functioning as a neurotransmitter and produced by activated macrophages. It is capable of killing tumour cells, parasites, and intracellular bacteria. (05 Mar 2000) |
| endothelio-endothelial placenta | A placenta in which the endothelium of the maternal vessels comes in direct contact with the endothelium of the foetal vessels to form the placental barrier. (05 Mar 2000) |
| fuchs' endothelial dystrophy | Disorder caused by loss of endothelium of the central cornea. It is characterised by hyaline endothelial outgrowths on descemet's membrane, epithelial blisters, reduced vision, and pain. (12 Dec 1998) |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
| platelet actomyosin | The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function. Synonym: thrombosthenin. (05 Mar 2000) |
| platelet adhesiveness | The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces. (12 Dec 1998) |
| platelet-aggregating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |